Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 17, 2022 / 01:00PM GMT
Release Date Price: $5.74 (+6.89%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. Welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I'm a SMid Cap Biotech Analyst. It is my great pleasure to introduce our next presenting company, Sangamo Therapeutics. With us today, we have Sandy Macrae, Chief Executive Officer.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Thank you, Gina. It's such a pleasure to be back out in the world and to be here with Gina in Miami and to talk to you about Sangamo.

As always, we refer you to our forward-looking statements. Sangamo is a fascinating company. We believe we have been a pioneer in the genomic medicines. We believe that we have compelling clinical data, scientific tool kit and the manufacturing infrastructure that is essential to underpin any genomic medicine company.

And we've been on a remarkable journey from the company the first pioneer at editing of cells, editing in vitro, editing in vivo to the first-generation Sangamo, where I'm

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot